Skip to main content
Contact Us
Subscribe
E-Edition
61°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Olema Pharmaceuticals Inc
(NQ:
OLMA
)
9.900
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
9.900
Bid (Size)
9.700 (1)
Ask (Size)
12.00 (2)
Prev. Close
9.900
Today's Range
9.900 - 9.900
52wk Range
3.640 - 17.79
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Performance
YTD
-27.90%
-27.90%
1 Month
-14.29%
-14.29%
3 Month
-11.69%
-11.69%
6 Month
-5.98%
-5.98%
1 Year
+147.50%
+147.50%
More News
Read More
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) Near the Top of Equities by Percentage Gain on 2/1
February 01, 2024
Via
Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/28
November 28, 2023
Via
Investor Brand Network
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
March 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/13
November 13, 2023
Via
Investor Brand Network
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Olema Oncology
Via
GlobeNewswire
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
February 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From
Olema Oncology
Via
GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/9
November 09, 2023
Via
Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/8
November 08, 2023
Via
Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Via
Investor's Business Daily
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Olema Oncology
Via
GlobeNewswire
$6.9M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
December 19, 2023
Via
Benzinga
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/7
November 07, 2023
Via
Investor Brand Network
Insiders Buying Walt Disney And 3 Other Stocks
December 11, 2023
Via
Benzinga
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023
From
Olema Oncology
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 27, 2023
Via
Benzinga
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
November 22, 2023
Via
Investor's Business Daily
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Olema Oncology
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
